IP Library Granted Patent US 12,060,593
Granted Patent B2
US 12,060,593 · App. 16/628,516 · Granted Aug 13, 2024

Fucosyltransferases and their use in producing fucosylated oligosaccharides

Inventors: Stefan Jennewein (Bad Honnef, DE); Katja Parschat (Bonn, DE)
Assignee: Chr. Hansen HMO GmbH
C12P19/18A23L33/125A23L33/21A23L33/40C12N9/1051C12N15/63C12Y204/01065
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,060,593
App. No.
16/628,516
Granted
Aug 13, 2024
Kind
B2
Abstract

Fucosyltransferases capable of transferring a fucose residue from a donor substrate to a lactotetraose, methods for producing fucosylated oligosaccharides utilizing the fucosyltransferases, and the use of the thus produced fucosylated oligosaccharides for manufacturing nutritional compositions are provided.

Claims (18)

1. A method for producing a fucosylated oligosaccharide, the method comprising:

a) providing at least one genetically engineered cell that has been engineered to express a heterologous fucosyltransferase, wherein the heterologous fucosyltransferase comprises an amino acid sequence having at least 80% sequence identity to one of SEQ ID NOs: 17-26 and 28-30, wherein the fucosyltransferase is capable of transferring a fucose residue from a donor substrate to an acceptor molecule;

b) cultivating by fermentation the at least one genetically engineered cell in the presence of at least one carbon source, an acceptor molecule being a lactotetraose, and a donor substrate, comprising a fucose residue, and under conditions suitable for the at least one genetically engineered cell to transfer the fucose residue from the donor substrate to the acceptor molecule to produce the fucosylated oligosaccharide.

2. The method according to claim 1 , wherein the acceptor molecule is selected from the group consisting of Lacto-N-tetraose (LNT) and Lacto-N-neotetraose (LNnT).

3. The method according to claim 2 , wherein the acceptor is LNT and the heterologous fucosyltransferase is selected from the group consisting of SEQ ID NOs: 18-22, 24, 25, 28 and 30, functional variants of the polypeptides of SEQ ID NOs: 18-22, 24, 25, 28 and 30 having at least 80% sequence identity to SEQ ID NOs: 18-22, 24, 25, 28, and 30.

4. The method according to claim 2 , wherein the acceptor is LNnT and the heterologous fucosyltransferase is selected from the group consisting of SEQ ID NOs: 17, 20, 26, 28, and 30, and functional variants of the polypeptides of SEQ ID NOs: 17, 20, 26, 28 and 30 having at least 80% sequence identity to SEQ ID NOs: 17, 20, 26, 28, and 30.

5. The method according to claim 2 , wherein the fucosyltransferase is encoded by a gene with a sequence selected from the group consisting of SEQ ID NOs: 5, 11, and 14.

6. The method according to claim 5 , wherein the gene has the sequence of SEQ ID NO: 14.

7. The method according to claim 2 , wherein the acceptor molecule is LNT and the fucosyltransferase is encoded by a gene having a sequence selected from the group consisting of SEQ ID NOs: 3-7, 9-11, and 14.

8. The method according to claim 2 , wherein the acceptor molecule is LNnT and the fucosyltransferase is encoded by a gene having a sequence selected from the group consisting of SEQ ID NOs: 2, 5, 11, 12, and 14.

9. The method according to claim 1 , wherein the heterologous fucosyltransferase is encoded by a nucleic acid molecule, wherein the nucleic acid molecule:

i) comprises a nucleotide sequence set forth in any one of SEQ ID NOs: 2-12 and 14-15.

ii) comprises a nucleotide sequence having a sequence identity of at least 80% to any one of SEQ ID NOs: 2-12 and 14-15 over the entire length of the sequence;

iii) comprises a nucleotide sequence which encodes a polypeptide having an amino acid sequence selected from any one of SEQ ID NOs: 17-26 and 28-30; or

iv) comprises a nucleotide sequence which encodes a polypeptide having at least 80% sequence identity to any one of SEQ ID NOs: 17-26 and 28-30.

10. The method according to claim 9 , wherein said genetically engineered cell is Escherichia coli and the nucleic acid molecule comprises a nucleotide sequence which encodes a polypeptide having at least 80% sequence identity to any one of SEQ ID NOs: 17-26, 28, and 30 that is codon-optimized for expression in Escherichia coli except if the nucleic acid molecule encodes the amino acid sequence of SEQ ID NO: 29.

11. The method according to claim 1 , wherein said at least one genetically engineered cell is Escherichia coli.

12. The method according to claim 1 , wherein the method further comprises recovering the fucosylated oligosaccharide.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 4, 2025
From: CHR. HANSEN HMO GMBH
To: CHR. HANSEN A/S
Reel/Frame 070396/0299 →
CHANGE OF NAME Recorded Apr 6, 2022
From: JENNEWEIN BIOTECHNOLOGIE GMBH
To: CHR. HANSEN HMO GMBH
Reel/Frame 059617/0804 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 11, 2020
From: JENNEWEIN, STEFAN; PARSCHAT, KATJA
To: JENNEWEIN BIOTECHNOLOGIE GMBH
Reel/Frame 052077/0193 →
Priority Claims (1)
EP 17180176 · Jul 7, 2017 · regional
Continuity (1)
Related Publication 20200181665A1 · Jun 11, 2020